Methods for the treatment of diabetic retinopathy and other ophthalmic diseases
US-10730825-B2 · Aug 4, 2020 · US
Methods for the treatment of diabetic retinopathy and other ophthalmic diseases
US11795136B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11795136-B2 |
| Application number | US-202016934715-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 21, 2020 |
| Priority date | May 4, 2012 |
| Publication date | Oct 24, 2023 |
| Grant date | Oct 24, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods are provided herein for the treatment of ophthalmic diseases or conditions such as an ophthalmic disease or disorder associated with diabetes in a patient. Also provided herein are methods of treating retinopathy of prematurity in a patient. Further, provided herein are methods for treating wet age-related macular degeneration in a patient. The methods comprise administration of compounds disclosed herein to a patient in need thereof that inhibit or slow one or more signs or symptoms of such conditions.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating an ophthalmic disease or disorder associated with neovascularization in the eye of a patient comprising administering a therapeutically effective amount of a composition comprising a compound, or stereoisomer, N-oxide or a pharmaceutically acceptable salt thereof, having the structure: wherein the ophthalmic disease or disorder associated with neovascularization is neovascular age-related macular degeneration; and wherein the composition is administered as a daily dose of about 2 mg; about 5 mg; about 7 mg; or about 10 mg. 2. The method of claim 1 , wherein the composition is administered to the patient orally. 3. The method of claim 1 , wherein treatment results in improvement of central vision in the patient. 4. The method of claim 1 , wherein the composition comprises (R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol hydrochloride.
Assignees
Inventors
Classifications
- C07C215/08Primary
with only one hydroxy group and one amino group bound to the carbon skeleton · CPC title
Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} · CPC title
- A61K31/138Primary
Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377) · CPC title
having six-membered rings with one oxygen as the only ring hetero atom · CPC title
Polymers containing oxygen · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11795136B2 cover?
- Methods are provided herein for the treatment of ophthalmic diseases or conditions such as an ophthalmic disease or disorder associated with diabetes in a patient. Also provided herein are methods of treating retinopathy of prematurity in a patient. Further, provided herein are methods for treating wet age-related macular degeneration in a patient. The methods comprise administration of compoun…
- Who is the assignee on this patent?
- Acucela Inc
- What technology area does this patent fall under?
- Primary CPC classification C07C215/08. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).